Abstract: An electrolyte solution containing at least one compound represented by formula (1-1) and formula (1-2), formula (1-1) being: where R101 is an optionally fluorinated C1-C7 alkyl group, an optionally fluorinated C2-C8 alkenyl group, an optionally fluorinated C2-C9 alkynyl group, or an optionally fluorinated C6-C12 aryl group, and optionally contains at least one selected from O, Si, S, and N in a structure; and formula (1-2) being: where R102 and R103 are (i) each individually H, F, an optionally fluorinated C1-C7 alkyl group, an optionally fluorinated C2-C7 alkenyl group, an optionally fluorinated C2-C9 alkynyl group, or an optionally fluorinated C5-C12 aryl group, or (ii) hydrocarbon groups binding to each other to form a 5-membered or 6-membered hetero ring with a nitrogen atom; and R102 and R103 each optionally contain at least one selected from O, S, and N in a structure.

Abstract: Disclosed is a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof. The variables in Formula (I) are defined herein. Compounds of Formula (I) are useful for inhibiting wild type c-kit kinase and for treating disorders and diseases mediated by wild type c-kit kinase in humans or non-humans.

Abstract: A nanocomposite hydrogel sheet and doxycycline loaded acne healing patches derived therefrom. The present invention relates to the biocompatible hydrogel sheet matrix comprising polyvinyl alcohol, linseed mucilage extract, nano zinc-oxide crosslinked dually via covalent linkages and free radical polymerization by e-beam exposure. The pore size of the nanocomposite hydrogel sheet ranges between 0.1-0.5 ?m. The doxycycline loaded acne patches derived from nanocomposite hydrogel sheet were able to inhibit the growth of S. aureus in an in vitro bacterial growth inhibition assay.

Abstract: Here we show that P. ananatis produces at least three phosphonates, two of which were purified and structurally characterized. The first, designated pantaphos, was shown to be 2-(hydroxy(phosphono)methyl)maleate; the second, a probable biosynthetic precursor, was shown to be 2-(phosphonomethyl)maleate. Purified pantaphos is both necessary and sufficient for the hallmark lesions of onion center rot. Moreover, when tested against mustard seedlings, the phytotoxic activity of pantaphos was comparable to the widely used herbicides glyphosate and phosphinothricin. Pantaphos was also active against a variety of human cell lines.

Abstract: The present invention is directed to methods of producing THC from CBD utilizing non-harsh methodology and resulting in substantially increased yields, as well as devices built upon these novel methods. The methods and devices are material efficient, and in certain embodiments, solvent-free. In particular, in certain embodiments, these methods and related devices are suitable for commercial production of THC from CBD. Furthermore, in certain embodiments, the present invention provides methods of producing THC from CBD in manner that affords tunability to select the ratio of THC-8 to THC-9.

Abstract: The present invention discloses methods of inhibiting biofilm formation, increasing bacteriocidal activity within a biofilm, treating bacteria within a biofilm, or remediating a biofilm in or on a subject, comprising administering to the subject an effective amount of a compound according to Formula I: wherein R1-5 are defined herein.

Abstract: The present invention is related to pharmaceutical formulations comprising a synthetic deoxypentitol and methods of use thereof in treating cancer.

Abstract: This invention teaches a class of fluorinated benzensulfonamides of general structure I, as shown: which are useful for inhibiting protein amyloid aggregation. The compounds taught can be used in pharmaceutical compositions in effective amounts to treat illnesses that result from protein amyloid aggregation.

Abstract: An iridium complex compound represented by formula (5): where in formula (5), Ir represents an iridium atom, R1 to R12 each independently represent a hydrogen atom or a substituent, adjacent R1 to R12 are optionally bonded together to form a ring, R13 to R22 each independently represent a hydrogen atom or a substituent, adjacent R13 to R22 are optionally bonded together to form a ring, X represents a bidentate ligand, m represents an integer of 1 to 3, and at least one of R13, R17, R18, and R22 represents a substituent other than a hydrogen atom.

Abstract: A therapeutic agent for treating at least one disease selected from the group consisting of inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases, comprising: at least one selected from the group consisting of a compound represented by the following general formula (1) and pharmacologically acceptable salts thereof as an active ingredient. [In the formula (1), R1 and R2 may be the same or different and each represents a hydrogen atom, a halogen atom, a hydroxyl group, a carboxy group, a cyano group, an optionally substituted C1-6 alkyl group et al.; R3 represents a hydrogen atom; R4 represents an optionally substituted 4- to 10-membered monocyclic heterocyclic group containing 1 to 4 heteroatoms selected from an oxygen atom, a nitrogen atom, and a sulfur atom; X represents a group represented by the following formula: —CH2—, —CH2—CH2—, —CH2—CH2—CH2—, or —CH2—O—CH2—; and Z represents a hydrogen atom or a hydroxyl group.

Abstract: The present invention is directed to a crystalline salt of 5-methyl-(6S)-tetrahydrofolic acid and L-isoleucine ethyl ester wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to L-isoleucine ethyl ester is from 1:0.3 to 1:2.0 (in mol/mol) and/or hydrates and/or solvates thereof, as well as, a process of obtaining the same.

Abstract: The invention relates to processes for preparing carbaprostacyclin analogues and intermediates prepared from the processes. The invention also relates to cyclopentenone intermediates in racemic or optically active form.

Abstract: The present invention relates to an improved process for the preparation of trazodone. In particular, the present invention relates to a continuous process for the preparation of trazodone. More in particular, the present invention relates to a new method for the preparation of trazodone, said method comprising at least one step consisting of a continuous process performed in a flow reactor.

Abstract: The invention relates to a platinum (ii) tetradentate onno complex luminescent material, preparation method and application thereof in organic light emitting diode. A platinum (II) tetradentate pyridine diphenol ONNO complex light-emitting material having the chemical structure of Formula (I) can be used for manufacturing organic light-emitting diodes emitting pure red light. The light-emitting material of the invention, because the end of the left side thereof is connected to benzofuran, has more red shift than the emission spectrum of the bipyridyl phenol ONNO-Pt(II) complex without a benzofuran group, and the anti-aggregation performance of the platinum(II) complex is effectively increased, as a B group is introduced on the phenolic ring on the right side thereof, so the self-quenching rate constant is low, and the color purity emitting deep red light and better luminous efficiency can be maintained in a certain range of doping concentration, which is more suitable for industrial preparation systems.

Abstract: Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating cancers or hematologic disorders.

Abstract: The present invention provides benzothiadiazine and chroman derivatives and particularly diazoxide and cromakalim derivatives for use in treating glaucoma, retinopathy, treating age related macular degeneration, treating, stabilizing and/or inhibiting blood and lymph vascularization, and reducing intraocular pressure by administering a pharmaceutically effective amount of a prodrug disposed in an ophthalmically acceptable carrier to the eye, wherein the prodrug specifically modulates a KATP channel to reduce an intraocular pressure.

Abstract: The invention relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): wherein L1, A, X1, X2, R1, R2, and R3 are described herein.

Abstract: The present disclosure provides imidazolyl compounds of Formula (I) and methods of preparing the compounds. The provided compounds are able to bind protein kinases and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase in a subject or cell and/or in treating or preventing a disease (e.g., proliferative disease, genetic disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. Also provided are pharmaceutical compositions, kits, methods, and uses that include or involve a compound described herein.

Abstract: The present invention relates to solid state forms of oclacitinib maleate and methods for the preparation of the solid state forms of oclacitinib maleate. The solid state forms of oclacitinib maleate of the present invention include amorphous oclacitinib maleate, crystalline tetramethyl urea solvate form of oclacitinib maleate, crystalline monohydrate form of oclacitinib maleate and crystalline form of oclacitinib maleate (form B).

Abstract: Disclosed embodiments relate to improved methods for the synthesis of activated fumarate intermediates and their use in chemical synthesis. Disclosed embodiments describe the synthesis of activated fumarate esters including those derived from activating groups including: 4-nitrophenyl, diphenylphophoryl azide, pivaloyl chloride, chlorosulfonyl isocyanate, p-nitrophenol, MEF, trifluoroacetyl and chlorine, for example, ethyl fumaroyl chloride and the subsequent use of the activated ester in situ. Further embodiments describe the improved synthesis of substituted aminoalkyl-diketopiperazines from unisolated and unpurified intermediates allowing for improved yields and reactor throughput.